Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial
| Autor: | Junichi Mukae, Takuya Komeno, Noriko Doki, Keisuke Tanaka, Atsushi Shinagawa, Takeshi Kobayashi, Kazuteru Ohashi, Takashi Kumagai, Megumi Akiyama, Naoki Wakimoto, Hiroshi Kojima, Daisuke Kudo, Shigeo Toyota, Yuichi Nakamura, Koh Yamamoto, Kazuhiko Kakihana, Tatsuya Saito, Hina Takano, Mitsuo Hori, Yuho Najima, Chikashi Yoshida, Masahide Yamamoto, Ikuyo Tsutsumi, Yasushi Okoshi, Takayuki Fujio, Aiko Igarashi |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Transplantation Autologous Gastroenterology Dexamethasone Drug Administration Schedule Bortezomib Young Adult 03 medical and health sciences 0302 clinical medicine Autologous stem-cell transplantation Japan Multicenter trial Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Cyclophosphamide Multiple myeloma Aged Bortezomib-Dexamethasone Regimen business.industry Hematopoietic Stem Cell Transplantation Induction chemotherapy Hematology General Medicine Middle Aged medicine.disease Hematologic Diseases Survival Analysis Regimen Treatment Outcome 030220 oncology & carcinogenesis Female Multiple Myeloma business Febrile neutropenia 030215 immunology medicine.drug |
| Zdroj: | Acta Haematologica. 141:111-118 |
| ISSN: | 1421-9662 0001-5792 |
| DOI: | 10.1159/000495338 |
| Popis: | We assessed the efficacy and safety of weekly cyclophosphamide-bortezomib-dexamethasone (CBD) induction prior to autologous stem cell transplantation (ASCT) in newly diagnosed Japanese patients with multiple myeloma (MM). This regimen consisted of four 28-day cycles of once-weekly oral cyclophosphamide (300 mg/m2), subcutaneous bortezomib (1.3 mg/m2), and oral dexamethasone (40 mg). Responding patients underwent stem cell collection followed by ASCT. The primary endpoint was the postinduction rate of achieving a near complete response (nCR) or better. Among the 38 enrolled patients, a complete response (CR), an nCR, a very good partial response (VGPR), and a partial response (PR) were achieved in 10.5, 2.6, 23.7, and 36.8% of cases, respectively. A grade 4 hematological adverse event (AE) was observed in 1 patient. Grade 3–4 infection, including febrile neutropenia, was observed in 4 patients (10.5%). Although 2 patients dropped out due to AE, 94.7% of the patients completed the induction phase. However, because of a poor response to induction chemotherapy ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|